Welcome to our dedicated page for Merus N.V. Common Shares news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus N.V. Common Shares stock.
Merus N.V. (Nasdaq: MRUS) is a clinical-stage immuno-oncology company focused on creating innovative therapies to treat and potentially cure cancer. At the heart of Merus' approach is its proprietary Biclonics® and Triclonics® technology platforms, which generate full-length human bispecific and trispecific antibodies. These advanced therapeutics are designed to engage the immune system to kill tumor cells and inhibit tumor cell growth pathways simultaneously.
Core Business
Merus' core business revolves around the discovery and development of bispecific antibody therapeutics. Their flagship technology, Biclonics®, can attack tumors in multiple ways, making them highly effective against various cancer types. The company’s portfolio includes several promising candidates, such as MCLA-128, which targets HER2 and HER3 receptors in gastric and breast cancers; MCLA-117, targeting AML; MCLA-158 (petosemtamab), focused on head and neck squamous cell carcinoma; and MCLA-145, developed for solid tumors.
Latest Achievements and News
As of May 2024, Merus has received the FDA's Breakthrough Therapy Designation (BTD) for petosemtamab in treating patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has progressed after treatment with platinum-based chemotherapy and PD-1/PD-L1 antibodies. This significant milestone is based on the promising data from the ongoing phase 1/2 trial of petosemtamab as a monotherapy, showing substantial improvement in clinically significant endpoints. Furthermore, Merus has announced plans to initiate a phase 3 trial in mid-2024 to evaluate the combination of petosemtamab and pembrolizumab in previously untreated patients.
Additionally, Merus revealed the acceptance of abstracts for MCLA-145 and MCLA-129 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These presentations highlighted the clinical activity of MCLA-145 in advanced solid tumors and the efficacy of MCLA-129 in non-small cell lung cancer (NSCLC).
Financial Condition and Partnerships
Merus has a solid financial foundation, bolstered by strategic partnerships and collaborations. Notably, Merus collaborates with Betta Pharmaceuticals to develop MCLA-129 in China while retaining global rights outside China. The company’s financial strategy includes advancing its clinical development programs and supporting preclinical research and technology development through successful capital raises.
About Merus N.V.
Merus N.V. is dedicated to the development of multispecific antibody therapeutics, referred to as Multiclonics®. These therapeutics have been observed in preclinical and clinical studies to exhibit the same features as conventional human monoclonal antibodies, including long half-life and low immunogenicity. For more information, visit Merus’ official website, Twitter, and LinkedIn.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced CEO Bill Lundberg's participation in several upcoming investor conferences. Key events include a panel discussion at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, a pre-recorded presentation at H.C. Wainwright 23rd Annual Global Investment Conference available on September 13, and a presentation at the 2021 Cantor Virtual Global Healthcare on September 27, 2021. The webcasts will be accessible on the company's investor page, with archived presentations available for a limited time.
Merus N.V. (Nasdaq: MRUS) reported its Q2 2021 financial results, with cash and equivalents rising to $352.8 million, expected to fund operations into H2 2024. Collaboration revenue surged to $12.4 million, primarily from Eli Lilly and Incyte. The company shared promising interim results from its Zeno program targeting NRG1 fusion cancers, showing 42% partial response in pancreatic cancer. Ongoing trials for MCLA-158 and MCLA-145 are set for updates in Q4 2021. However, R&D expenses increased, leading to a net loss of $27.4 million for the quarter.
Merus N.V. (Nasdaq: MRUS) announced the novel mechanism of action for its clinical-stage Biclonics® T-cell agonist, MCLA-145, which targets PD-L1 and CD137. Published in Nature Communications, the study reveals MCLA-145's ability to activate immune T cells in tumor microenvironments while blocking inhibitory signals. Currently, MCLA-145 is in a phase 1 multicenter dose escalation study for solid tumors, with Merus retaining U.S. commercialization rights, while Incyte holds rights outside the U.S.
On July 7, 2021, Merus N.V. (Nasdaq: MRUS) announced that CEO Bill Lundberg, M.D. will participate in the panel discussion titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies at William Blair's Biotech Focus Conference 2021. The event is scheduled for July 14 at 11:20 a.m. ET. Investors can access the live webcast on the Company's website, with an archived presentation available for a limited time.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®.
Merus has shared interim efficacy data from the phase 1/2 eNRGy trial for zenocutuzumab (Zeno) in patients with NRG1+ cancers, with 61 patients enrolled as of April 13, 2021. Notable findings reveal a 42% overall response rate in pancreatic cancer and a 29% rate across various NRG1+ tumor types. Zeno demonstrates a favorable safety profile, with most adverse events being mild or moderate. The company plans to discuss these results further in an investor call on June 6, 2021.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2 at 9:00 a.m. ET. The session will be accessible via a live webcast on the company's Investors page, with an archived version available afterward. Merus focuses on developing innovative multispecific antibodies, particularly its Biclonics® and Triclonics® products, which aim to advance cancer treatment.
Merus N.V. (MRUS) announced interim results from its phase 1/2 eNRGy trial investigating zenocutuzumab (Zeno) in patients with NRG1+ cancers. As of January 12, 2021, 51 patients were treated, with 33 evaluable for response, showing 27% overall response rate (ORR) and 40% ORR in pancreatic cancer. The safety profile remains favorable, with most adverse events mild or moderate. An oral presentation of updated interim analysis is set for ASCO on June 4, and an investor call is planned for June 6 to discuss results and provide program updates.
Merus N.V. (Nasdaq: MRUS) announced new collaborations in Israel, Italy, and Spain to enhance molecular screening for patients with cancers linked to neuregulin 1 (NRG1) fusions and promote the eNRGy clinical trial for its bispecific antibody, zenocutuzumab (Zeno). Progenetics, AISP, and Universidad de Navarra will educate patients and oncologists about these screenings. This initiative aims to improve patient treatment options and potentially recruit more patients for the eNRGy trial, which evaluates Zeno's safety and efficacy in treating NRG1+ cancers.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18 at 8:00 a.m. ET. The presentation will be available via a live webcast on the company's Investors page, with an archived version accessible for a limited time afterward.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®, aiming to provide advanced therapeutic options in cancer treatment.
Merus N.V. (Nasdaq: MRUS) announced its Q1 2021 financial results, showing a total revenue of $8.35 million, a significant increase from $6.30 million in Q1 2020. The operating loss was $21.79 million, up from $19.57 million year-over-year. Cash and equivalents rose to $374.4 million, bolstered by a follow-on offering and a $60 million collaboration with Lilly. Key highlights include the upcoming ASCO presentation on zenocutuzumab and the advancement of its clinical pipeline with MCLA-145 and MCLA-129 trials. Additionally, Cecile Geuijen was promoted to Chief Scientific Officer.
FAQ
What is the current stock price of Merus N.V. Common Shares (MRUS)?
What is the market cap of Merus N.V. Common Shares (MRUS)?
What is the core business of Merus N.V.?
What are some of Merus' key product candidates?
What significant recent achievement has Merus reported?
What are Biclonics®?
What is the status of MCLA-145 and MCLA-129?
What are Multiclonics®?
Who are Merus' key partners?
What are the financial strategies of Merus?
What is the purpose of the latest capital raise by Merus?
Where can I find more information about Merus N.V.?
